NASDAQ · PRME
Prime Medicine, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PRME: Nov 6, 2026
Prime Medicine, Inc. Common Stock is estimated to report earnings on 11/06/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.23. The reported EPS for the same quarter last year was $-0.32.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.23 | $-0.19 | $-0.28 | 6 |
| Dec 2026 | $-0.24 | $-0.17 | $-0.32 | 6 |
| Mar 2027 | $-0.21 | $-0.19 | $-0.22 | 3 |
| Jun 2027 | $-0.22 | $-0.21 | $-0.23 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Quiver Quantitative · InvestorPlace- Quiver Quantitative · Jul 21, 10:46 AM EDT$PRME stock is up 16% today. Here's what we see in our data.$PRME stock has now risen 16% today, according to our price data from Polygon. There has been approximately $18,949,952 of trading volume.
- Quiver Quantitative · Jul 16, 7:13 AM EDTPrime Medicine Secures Up to $24 Million from Cystic Fibrosis Foundation to Advance Prime Editing Technology for Cystic Fibrosis TreatmentPrime Medicine secures up to $24 million from the CF Foundation to advance Prime Editors for cystic fibrosis treatment.
- Quiver Quantitative · Jul 9, 7:37 PM EDT$PRME stock is up 12% today. Here's what we see in our data.$PRME stock has now risen 12% today, according to our price data from Polygon. There has been approximately $40,040,828 of trading volume.
- Quiver Quantitative · Jul 2, 11:31 AM EDT$PRME stock is up 20% today. Here's what we see in our data.$PRME stock has now risen 20% today, according to our price data from Polygon. There has been approximately $9,899,126 of trading volume.
- Quiver Quantitative · Jun 17, 11:31 AM EDT$PRME stock is up 13% today. Here's what we see in our data.$PRME stock has now risen 13% today, according to our price data from Polygon. There has been approximately $7,065,505 of trading volume.
- Quiver Quantitative · Jun 12, 5:02 PM EDTInsider Purchase: 10% owner at $PRME Buys 21,000 SharesDavid R. Liu, a 10% owner of $PRME, bought 21,000 shares of the company on 06-11-2025 for an estimated $33,589. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of this class of stock by approximately 0.1%. Followin
- Quiver Quantitative · Jun 5, 11:31 AM EDT$PRME stock is up 7% today. Here's what we see in our data.$PRME stock has now risen 7% today, according to our price data from Polygon. There has been approximately $1,269,516 of trading volume.
- Quiver Quantitative · May 19, 8:42 AM EDTPrime Medicine, Inc. Announces Positive Phase 1/2 Data for PM359 and Strategic Restructuring Focused on Liver Disease ProgramsPrime Medicine announces positive Phase 1/2 data for PM359, leadership changes, and strategic pipeline prioritization, focusing on liver diseases.
- Quiver Quantitative · May 19, 8:42 AM EDTPrime Medicine Reports Positive Initial Clinical Data for PM359 in First Human Trial for Chronic Granulomatous DiseasePrime Medicine reports positive initial Phase 1/2 trial results for PM359, showing safety and efficacy in treating Chronic Granulomatous Disease.
- Quiver Quantitative · May 7, 5:06 PM EDTPRIME MEDICINE Earnings Preview: Recent $PRME Insider Trading, Hedge Fund Activity, and MorePRIME MEDICINE ($PRME) is expected to release its quarterly earnings data on Friday, May 9th before market open, per Finnhub. Analysts are expecting revenue of $1,069,857 and earnings of -$0.33 per share.
- Quiver Quantitative · Mar 18, 7:11 AM EDTPrime Medicine Announces Preclinical Program for Alpha-1 Antitrypsin Deficiency Utilizing Prime Editing TechnologyPrime Medicine announces promising preclinical results for a novel AATD treatment using advanced Prime Editing technology, aiming for clinical trials by mid-2026.
- InvestorPlace · May 17, 6:27 AM EDTWall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024InvestorPlace – Stock Market News, Stock Advice & Trading Tips
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Prime Medicine, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.